Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

REVB | Revelation Biosciences Inc

Index	-	P/E	-	EPS (ttm)	-0.11	Insider Own	2.17%	Shs Outstand	6.30M	Perf Week	-5.94%
Market Cap	4.32M	Forward P/E	-	EPS next Y	-1.43	Insider Trans	23.48%	Shs Float	6.16M	Perf Month	-0.45%
Income	2.33M	PEG	-	EPS next Q	-0.34	Inst Own	12.79%	Short Float / Ratio	0.11% / 0.07	Perf Quarter	-25.07%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-44.79%	Short Interest	0.01M	Perf Half Y	-52.72%
Book/sh	1.81	P/B	0.38	EPS next Y	-	ROA	23.10%	Target Price	15.00	Perf Year	-92.47%
Cash/sh	2.49	P/C	0.27	EPS next 5Y	-	ROE	48.74%	52W Range	0.64 - 17.55	Perf YTD	-89.70%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	20.44%	52W High	-96.09%	Beta	0.25
Dividend %	-	Quick Ratio	3.45	Sales past 5Y	0.00%	Gross Margin	-	52W Low	7.12%	ATR	0.07
Employees	6	Current Ratio	3.45	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	40.99	Volatility	9.08% 9.52%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	94.15%	Profit Margin	-	Rel Volume	0.35	Prev Close	0.68
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 11 AMC	Payout	-	Avg Volume	95.68K	Price	0.69
Recom	1.00	SMA20	-6.36%	SMA50	-9.26%	SMA200	-73.88%	Volume	33,210	Change	0.82%

Aug-14-23 07:36AM	REVB Reports Solid Balance Sheet and Remains on Track (Zacks Small Cap Research)
Aug-11-23 04:10PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023 (Business Wire)
Jun-29-23 09:00AM	REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders (Business Wire)
Jun-22-23 10:24AM	REVB: REVB Looks Attractive Ahead of Trials (Zacks Small Cap Research)
Jun-12-23 04:15PM	Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal (Business Wire)
09:00AM	Loading…
May-22-23 09:00AM	Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress (Business Wire) +7.21%
Mar-30-23 05:42PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress (Business Wire)
Mar-13-23 09:00AM	Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board (Business Wire)
Mar-06-23 09:00AM	Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference (Business Wire)
Feb-13-23 04:20PM	Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering (Business Wire)
Feb-09-23 09:42AM	Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering (Business Wire) -48.51%
Feb-07-23 09:00AM	Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300 (Business Wire) -22.65%
Jan-31-23 12:00PM	Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders (Business Wire) +5.26%
Jan-10-23 09:00AM	Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023 (Business Wire)
Nov-18-22 09:00AM	Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model (Business Wire)
04:30PM	Loading…
Nov-10-22 04:30PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress (Business Wire) +7.79%
Oct-25-22 11:13AM	Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease (Business Wire) +64.60%
09:00AM	Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease (Business Wire)
Oct-06-22 07:00AM	Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement (Business Wire) +14.44%
Aug-15-22 05:30PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress (GlobeNewswire)
Jul-29-22 11:45AM	Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering (GlobeNewswire) -6.10%
Jul-26-22 08:15AM	Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering (GlobeNewswire) -51.39%
Jul-22-22 06:30PM	Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire) -23.04%
Jul-14-22 09:00AM	Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire) +16.10%
Jun-13-22 09:00AM	Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire) -12.73%
May-23-22 09:00AM	Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire)
May-16-22 04:01PM	Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress (GlobeNewswire)
Apr-06-22 09:00AM	Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update (GlobeNewswire)
Mar-30-22 09:00AM	Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection (GlobeNewswire) -38.32%
Mar-24-22 09:00AM	Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection (GlobeNewswire) +11.94%
09:00AM	Loading…
Mar-22-22 09:00AM	Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC (GlobeNewswire) +6.54%
Mar-15-22 09:00AM	Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection (GlobeNewswire) +22.55%
Mar-08-22 09:00AM	Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference (GlobeNewswire)
Feb-07-22 09:00AM	Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference (GlobeNewswire) +9.58%
Jan-24-22 08:00AM	Revelation Biosciences Raises $7.76 Million in Equity Financing (GlobeNewswire) -19.15%
Jan-20-22 09:00AM	Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection (GlobeNewswire) -18.50%
Jan-18-22 09:00AM	Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis (GlobeNewswire) -27.25%
Jan-13-22 01:54PM	REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company (GlobeNewswire) -19.03%

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TIDMARSH GEORGE F	Director	Sep 18	Sale	0.74	4,000	2,960	39,348	Sep 18 05:18 PM
TIDMARSH GEORGE F	Director	Sep 15	Sale	0.73	9,500	6,935	43,348	Sep 18 05:18 PM
TIDMARSH GEORGE F	Director	Sep 14	Sale	0.75	12,000	9,000	52,848	Sep 18 05:18 PM
TIDMARSH GEORGE F	Director	Apr 18	Buy	1.16	25,000	29,000	64,848	Apr 19 06:00 PM
TIDMARSH GEORGE F	Director	Apr 17	Buy	1.16	26,500	30,740	39,848	Apr 19 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REVB | Revelation Biosciences Inc

Upgrade your FINVIZ experience